4.5 Review

A Comprehensive Review of the Pleiotropic Effects of Ticagrelor

期刊

CARDIOVASCULAR DRUGS AND THERAPY
卷 -, 期 -, 页码 -

出版社

SPRINGER
DOI: 10.1007/s10557-022-07373-5

关键词

P2Y(12) inhibitor; Ticagrelor; Pleiotropic effects; Aspirin; Ischemia-reperfusion injury; Myocardial infarction; Coronary artery disease; Systematic review

资金

  1. John S. Dunn Chair in Cardiology Research and Education [B2017/BMD-3738]

向作者/读者索取更多资源

This review summarizes the pleiotropic effects of ticagrelor, including attenuation of ischemia-reperfusion injury, inflammation, adverse cardiac remodeling, and atherosclerosis. Ticagrelor exerts these effects by increasing local interstitial adenosine levels and activating downstream cardio-protective molecules. High-dose aspirin and caffeine, as well as statins, may mediate the attenuation and augmentation of these effects.
Aims This review summarizes the findings of preclinical studies evaluating the pleiotropic effects of ticagrelor. These include attenuation of ischemia-reperfusion injury (IRI), inflammation, adverse cardiac remodeling, and atherosclerosis. In doing so, it aims to provide novel insights into ticagrelor's mechanisms and benefits over other P2Y(12) inhibitors. It also generates viable hypotheses for the results of seminal clinical trials assessing ticagrelor use in acute and chronic coronary syndromes. Methods and Results A comprehensive review of the preclinical literature demonstrates that ticagrelor protects against IRI in the setting of both an acute myocardial infarction (MI), and when MI occurs while on chronic treatment. Maintenance therapy with ticagrelor also likely mitigates adverse inflammation, cardiac remodeling, and atherosclerosis, while improving stem cell recruitment. These effects are probably mediated by ticagrelor's ability to increase local interstitial adenosine levels which activate downstream cardio-protective molecules. Attenuation and augmentation of these pleiotropic effects by high-dose aspirin and caffeine, and statins respectively may help explain variable outcomes in PLATO and subsequent randomized controlled trials (RCTs). Conclusion Most RCTs and meta-analyses have not evaluated the pleiotropic effects of ticagrelor. We need further studies comparing cardiovascular outcomes in patients treated with ticagrelor versus other P2Y(12) inhibitors that are mindful of the unique pleiotropic advantages afforded by ticagrelor, as well as possible interactions with other therapies (e.g., aspirin, statins, caffeine).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据